001     57304
005     20161225215125.0
024 7 _ |2 WOS
|a WOS:000239765700008
037 _ _ |a PreJuSER-57304
041 _ _ |a eng
082 _ _ |a 610
084 _ _ |2 WoS
|a Radiology, Nuclear Medicine & Medical Imaging
100 1 _ |a Risse, J. H.
|b 0
|0 P:(DE-HGF)0
245 _ _ |a Therapy of hepatocellular carcinoma with iodine-131-lipiodol: results in a large German cohort
260 _ _ |a Stuttgart
|b Schattauer
|c 2006
300 _ _ |a 185 - 192
336 7 _ |a Journal Article
|0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|0 0
|2 EndNote
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a article
|2 DRIVER
440 _ 0 |a Nuklearmedizin
|x 0029-5566
|0 4657
|v 45
500 _ _ |a Record converted from VDB: 12.11.2012
520 _ _ |a Aim: To evaluate the efficacy and tolerance of iodine-I-131-lipiodol (I-131-lipiodol) for hepatocellular carcinoma (HCC) in German long term patients and comparison with medically treated controls. Patients, Methods: 38 courses of intro-arterial I-131-lipiodol therapy with a total activity up to 6.7 GBq were performed in 18 patients with HCC (6 with portal vein thrombosis). Liver and tumour volume and lipiodol deposition were measured by computed tomography and I-131 activity by scintigraphy. Therapeutic efficacy was determined by tumour volume change and matched-pairs analysis in comparison to medically (i.e. tamoxifen or medical support) treated patients. Results: Tumour volume decreased in 20/32 index nodules (63%) after the first course. Repeated therapy frequently resulted in further tumour reduction. Overall response to treatment was partial in 11 nodules, minor response in 4 nodules, and disease was stable in 12 and progressive in 5. Significant response was associated with pretherapeutic nodule volume up to 150 ml (diameter of 6.6 cm). Survival rate after 3, 6, 9, 12, 24 and 36 months was 78, 61, 50, 39, 17, and 6%. Matched-pairs analysis of survival revealed I-131-lipiodol to be superior to medical treatment. The most important side effect was a pancreatitis-like syndrome whereas overall tolerance was good. Conclusion: The long term results confirm that HCC therapy with I-131-lipiodol is effective and probably superior to medical treatment. Tumour nodules of up to 6 cm diameter are well suited for this therapy even in the presence of portal vein thrombosis.
536 _ _ |a Funktion und Dysfunktion des Nervensystems
|c P33
|2 G:(DE-HGF)
|0 G:(DE-Juel1)FUEK409
|x 0
588 _ _ |a Dataset connected to Web of Science
650 _ 7 |a J
|2 WoSType
653 2 0 |2 Author
|a hepatocellular carcinoma
653 2 0 |2 Author
|a cancer therapy
653 2 0 |2 Author
|a iodine-131-lipiodol
653 2 0 |2 Author
|a portal vein thrombosis
653 2 0 |2 Author
|a long term analysis
700 1 _ |a Rabe, C.
|b 1
|0 P:(DE-HGF)0
700 1 _ |a Pauleit, D.
|b 2
|u FZJ
|0 P:(DE-Juel1)VDB6977
700 1 _ |a Reichmann, K.
|b 3
|0 P:(DE-HGF)0
700 1 _ |a Menzel, C.
|b 4
|0 P:(DE-HGF)0
700 1 _ |a Grünwald, F.
|b 5
|0 P:(DE-HGF)0
700 1 _ |a Strunk, H.
|b 6
|0 P:(DE-HGF)0
700 1 _ |a Biersack, H.-J.
|b 7
|0 P:(DE-HGF)0
700 1 _ |a Palmedo, H.
|b 8
|0 P:(DE-HGF)0
773 _ _ |g Vol. 45, p. 185 - 192
|p 185 - 192
|q 45<185 - 192
|0 PERI:(DE-600)2030804-8
|t Nuklearmedizin
|v 45
|y 2006
|x 0029-5566
909 C O |o oai:juser.fz-juelich.de:57304
|p VDB
913 1 _ |k P33
|v Funktion und Dysfunktion des Nervensystems
|l Funktion und Dysfunktion des Nervensystems
|b Gesundheit
|0 G:(DE-Juel1)FUEK409
|x 0
914 1 _ |a Nachtrag
|y 2006
915 _ _ |0 StatID:(DE-HGF)0010
|a JCR/ISI refereed
920 1 _ |k IME
|l Institut für Medizin
|d 31.12.2006
|g IME
|0 I:(DE-Juel1)VDB54
|x 1
970 _ _ |a VDB:(DE-Juel1)90124
980 _ _ |a VDB
980 _ _ |a ConvertedRecord
980 _ _ |a journal
980 _ _ |a I:(DE-Juel1)INB-3-20090406
980 _ _ |a UNRESTRICTED
981 _ _ |a I:(DE-Juel1)INB-3-20090406


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21